CommercialAdministrativeMedium impact
[California] Lenalidomide is now available with end‑to‑end REMS support
Anthem BCBS·CA · Oncology, Hematology·Provider Bulletin
Effective date
May 1, 2026
We identified it
May 3, 2026
Summary
Anthem Blue Cross (California) now offers lenalidomide through BioPlus Specialty Pharmacy with end-to-end REMS (Risk Evaluation and Mitigation Strategies) management. This streamlines prior authorization and therapy initiation for oncology/hematology practices, with BioPlus handling the full REMS process to reduce administrative burden and accelerate patient access to treatment.
Action Required
Effective May 1, 2026: Oncology and hematology providers prescribing lenalidomide to Anthem Blue Cross California members should route all new prescriptions and REMS management through BioPlus Specialty Pharmacy (NCPDP 1078535, Fax: 800-269-5493, bioplusrx.com) instead of previous channels. Billing and clinical staff should update internal referral lists and provider workflows to direct lenalidomide cases to BioPlus. Communicate this change to prescribers and front-desk staff to ensure proper routing. Use Availity Chat with Payer (https://Availity.com) during business hours for eligibility, authorization, and claims status questions. Failure to route through BioPlus may delay REMS approval and therapy initiation.